Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia (Q41724569)

8 October 2017

Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia (English)

1 reference

8 October 2017

1 reference

1

0 references

Iuri Marinov

5

0 references

author name string

Cyril Šálek

1

1 reference

8 October 2017

František Folber

2

1 reference

8 October 2017

Eva Froňková

3

1 reference

8 October 2017

Bohumír Procházka

4

1 reference

8 October 2017

Iuri Marinov

5

1 reference

8 October 2017

Petr Cetkovský

6

1 reference

8 October 2017

Jiří Mayer

7

1 reference

8 October 2017

Michael Doubek

8

1 reference

8 October 2017

Czech Leukemia Study Group - for Life

9

1 reference

8 October 2017

21 May 2015

1 reference

European Journal of Haematology

8 October 2017

1 reference

8 October 2017

96

1 reference

8 October 2017

276-284

1 reference

8 October 2017

3

1 reference

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

8 October 2017

1 reference

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

21 January 2018

1 reference

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

21 January 2018

1 reference

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.

21 January 2018

1 reference

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

21 January 2018

1 reference

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

21 January 2018

1 reference

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

21 January 2018

1 reference

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

21 January 2018

1 reference

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

21 January 2018

1 reference

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

21 January 2018

1 reference

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12587

1 reference

8 October 2017

1 reference